{"id":70113,"date":"2026-07-16T18:27:02","date_gmt":"2026-07-16T10:27:02","guid":{"rendered":"https:\/\/flcube.com\/?p=70113"},"modified":"2026-07-16T18:27:03","modified_gmt":"2026-07-16T10:27:03","slug":"china-resources-pharmaceutical-to-acquire-23-5-stake-in-lier-chemical-to-advance-synthetic-biology-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70113","title":{"rendered":"China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>China Resources Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3320:HKG\">HKG: 3320<\/a>) announced today its plan to acquire <strong>188,102,749 shares<\/strong> of <strong>Lier Chemical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002258:SHE\">SHE: 002258<\/a>), representing approximately <strong>23.50%<\/strong> of Lier Chemical&#8217;s total equity. The strategic investment will accelerate the industrialization of China Resources Pharmaceutical&#8217;s synthetic biology technologies and product pipeline.<\/p>\n\n\n\n<h2 id=\"h-transaction-details-key-metrics\" class=\"wp-block-heading\">Transaction Details | Key Metrics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>China Resources Pharmaceutical (HKG: 3320)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Lier Chemical (SHE: 002258)<\/td><\/tr><tr><td><strong>Shares Acquired<\/strong><\/td><td>188,102,749 shares<\/td><\/tr><tr><td><strong>Equity Stake<\/strong><\/td><td>23.50% of total equity<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>July 15, 2026<\/td><\/tr><tr><td><strong>Transaction Type<\/strong><\/td><td>Strategic minority investment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-synthetic-biology-platform\" class=\"wp-block-heading\">Strategic Rationale &amp; Synthetic Biology Platform<\/h2>\n\n\n\n<h3 id=\"h-platform-development-timeline\" class=\"wp-block-heading\">Platform Development Timeline<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Since <strong>2022<\/strong>, China Resources Pharmaceutical has systematically expanded its synthetic biology capabilities through <strong>China Resources Double-Crane<\/strong>, establishing:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Seven major technology platforms<\/strong> across synthetic biology applications<\/li>\n\n\n\n<li><strong>Four key focus areas<\/strong> for commercial development<\/li>\n\n\n\n<li><strong>Integrated pipeline<\/strong> from research to industrialization<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-core-focus-areas\" class=\"wp-block-heading\">Core Focus Areas<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The company&#8217;s synthetic biology strategy targets four high-value sectors:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>API Intermediates:<\/strong> Active Pharmaceutical Ingredient intermediates for pharmaceutical manufacturing<\/li>\n\n\n\n<li><strong>Novel Health Foods:<\/strong> Bioengineered nutritional products and functional foods<\/li>\n\n\n\n<li><strong>Crop Protection &amp; Animal Health:<\/strong> Pesticides, veterinary drugs, and agricultural biologics<\/li>\n\n\n\n<li><strong>New Materials &amp; Green Energy:<\/strong> Sustainable materials and bio-based energy solutions<\/li>\n<\/ol>\n\n\n\n<h3 id=\"h-industrialization-strategy\" class=\"wp-block-heading\">Industrialization Strategy<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Lier Chemical investment represents a critical step in <strong>scaling synthetic biology production<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing Capacity:<\/strong> Leverages Lier Chemical&#8217;s existing chemical production infrastructure<\/li>\n\n\n\n<li><strong>Technology Transfer:<\/strong> Enables rapid scale-up of laboratory-developed processes<\/li>\n\n\n\n<li><strong>Commercial Integration:<\/strong> Bridges gap between R&amp;D and market-ready products<\/li>\n\n\n\n<li><strong>Supply Chain Control:<\/strong> Secures manufacturing capabilities for proprietary compounds<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-target-company-profile-lier-chemical\" class=\"wp-block-heading\">Target Company Profile: Lier Chemical<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Lier Chemical<\/strong> (SHE: 002258) is an established Chinese chemical manufacturer with expertise in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fine chemical synthesis<\/strong> and large-scale production<\/li>\n\n\n\n<li><strong>Pharmaceutical intermediates<\/strong> manufacturing<\/li>\n\n\n\n<li><strong>Agrochemical production<\/strong> capabilities<\/li>\n\n\n\n<li><strong>Chemical engineering<\/strong> and process optimization<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The 23.5% stake positions China Resources Pharmaceutical as a <strong>significant minority shareholder<\/strong> with substantial influence over strategic direction while maintaining Lier Chemical&#8217;s operational independence.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-implications\" class=\"wp-block-heading\">Market Context &amp; Competitive Implications<\/h2>\n\n\n\n<h3 id=\"h-synthetic-biology-investment-trend\" class=\"wp-block-heading\">Synthetic Biology Investment Trend<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This transaction reflects the broader trend of <strong>pharmaceutical companies investing in synthetic biology<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Convergence:<\/strong> Integration of biological and chemical manufacturing<\/li>\n\n\n\n<li><strong>Sustainability Drive:<\/strong> Bio-based production replacing traditional chemical synthesis<\/li>\n\n\n\n<li><strong>Supply Chain Resilience:<\/strong> Domestic production of critical intermediates and APIs<\/li>\n\n\n\n<li><strong>Innovation Acceleration:<\/strong> Faster development cycles through engineered biological systems<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-strategic-advantages\" class=\"wp-block-heading\">Strategic Advantages<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">For China Resources Pharmaceutical, the acquisition provides:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vertical Integration:<\/strong> Control over key manufacturing steps in synthetic biology value chain<\/li>\n\n\n\n<li><strong>Scale Economies:<\/strong> Leveraging existing chemical production facilities for biological products<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Diversified manufacturing base across multiple therapeutic and industrial sectors<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Proprietary bio-manufacturing capabilities vs. traditional pharma peers<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-financial-implications\" class=\"wp-block-heading\">Financial Implications<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">While specific transaction value was not disclosed, the strategic nature suggests:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Long-term Investment Horizon:<\/strong> Focus on platform development rather than short-term returns<\/li>\n\n\n\n<li><strong>Capital Allocation Priority:<\/strong> Synthetic biology as core growth driver for the organization<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> Expansion beyond traditional pharmaceutical distribution and manufacturing<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-looking-strategic-impact\" class=\"wp-block-heading\">Forward-Looking Strategic Impact<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This investment positions China Resources Pharmaceutical at the forefront of China&#8217;s <strong>synthetic biology industrialization<\/strong> efforts, aligning with national priorities for:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biomanufacturing sovereignty<\/strong> in critical supply chains<\/li>\n\n\n\n<li><strong>Green chemistry<\/strong> and sustainable production methods<\/li>\n\n\n\n<li><strong>Pharmaceutical innovation<\/strong> through advanced biological platforms<\/li>\n\n\n\n<li><strong>Agricultural technology<\/strong> modernization and food security<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The integration of Lier Chemical&#8217;s manufacturing expertise with China Resources&#8217; synthetic biology platforms could create a <strong>vertically integrated bio-manufacturing powerhouse<\/strong> capable of serving multiple high-growth markets simultaneously.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding strategic investments, business development, and market opportunities. Actual results may differ due to risks including regulatory approvals, market dynamics, and integration challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071501453_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026071501453_c.\"><\/object><a id=\"wp-block-file--media-d9731419-01ac-442c-a0a8-fe42ccdbb720\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071501453_c.pdf\">2026071501453_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071501453_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d9731419-01ac-442c-a0a8-fe42ccdbb720\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China Resources Pharmaceutical (HKG: 3320) announced today its plan to acquire 188,102,749 shares of Lier&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1975,1976,4858,4859],"class_list":["post-70113","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-china-resources-pharmaceutical","tag-hkg-3320","tag-lier-chemical","tag-she-002258"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Resources Pharmaceutical (HKG: 3320) announced today its plan to acquire 188,102,749 shares of Lier Chemical (SHE: 002258), representing approximately 23.50% of Lier Chemical&#039;s total equity. The strategic investment will accelerate the industrialization of China Resources Pharmaceutical&#039;s synthetic biology technologies and product pipeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70113\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline\" \/>\n<meta property=\"og:description\" content=\"China Resources Pharmaceutical (HKG: 3320) announced today its plan to acquire 188,102,749 shares of Lier Chemical (SHE: 002258), representing approximately 23.50% of Lier Chemical&#039;s total equity. The strategic investment will accelerate the industrialization of China Resources Pharmaceutical&#039;s synthetic biology technologies and product pipeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70113\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T10:27:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T10:27:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70113#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70113\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline\",\"datePublished\":\"2026-07-16T10:27:02+00:00\",\"dateModified\":\"2026-07-16T10:27:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70113\"},\"wordCount\":561,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China Resources Pharmaceutical\",\"HKG: 3320\",\"Lier Chemical\",\"SHE: 002258\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70113#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70113\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70113\",\"name\":\"China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-16T10:27:02+00:00\",\"dateModified\":\"2026-07-16T10:27:03+00:00\",\"description\":\"China Resources Pharmaceutical (HKG: 3320) announced today its plan to acquire 188,102,749 shares of Lier Chemical (SHE: 002258), representing approximately 23.50% of Lier Chemical's total equity. The strategic investment will accelerate the industrialization of China Resources Pharmaceutical's synthetic biology technologies and product pipeline.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70113#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70113\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70113#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"China Resources Pharmaceutical (HKG: 3320) announced today its plan to acquire 188,102,749 shares of Lier Chemical (SHE: 002258), representing approximately 23.50% of Lier Chemical's total equity. The strategic investment will accelerate the industrialization of China Resources Pharmaceutical's synthetic biology technologies and product pipeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70113","og_locale":"en_US","og_type":"article","og_title":"China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline","og_description":"China Resources Pharmaceutical (HKG: 3320) announced today its plan to acquire 188,102,749 shares of Lier Chemical (SHE: 002258), representing approximately 23.50% of Lier Chemical's total equity. The strategic investment will accelerate the industrialization of China Resources Pharmaceutical's synthetic biology technologies and product pipeline.","og_url":"https:\/\/flcube.com\/?p=70113","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T10:27:02+00:00","article_modified_time":"2026-07-16T10:27:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70113#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70113"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline","datePublished":"2026-07-16T10:27:02+00:00","dateModified":"2026-07-16T10:27:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70113"},"wordCount":561,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China Resources Pharmaceutical","HKG: 3320","Lier Chemical","SHE: 002258"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70113#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70113","url":"https:\/\/flcube.com\/?p=70113","name":"China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-16T10:27:02+00:00","dateModified":"2026-07-16T10:27:03+00:00","description":"China Resources Pharmaceutical (HKG: 3320) announced today its plan to acquire 188,102,749 shares of Lier Chemical (SHE: 002258), representing approximately 23.50% of Lier Chemical's total equity. The strategic investment will accelerate the industrialization of China Resources Pharmaceutical's synthetic biology technologies and product pipeline.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70113#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70113"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70113#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70113"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70113\/revisions"}],"predecessor-version":[{"id":70115,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70113\/revisions\/70115"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}